SCHEMBL4968650

SCHEMBL4968650

CCn1ncc(C(=O)O)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NR4A3 Q92570 1/20 0.41
HTT P42858 1/20 0.40
ALKBH1 Q13686 1/20 0.40
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PDE5A O76074 1/20 0.37
NPC1 O15118 3/20 0.37
MEN1 O00255 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716749 0.83 AGTR1 (0.41) NR4A3ALKBH1L3MBTL1
SCHEMBL23319033 0.80 LMNA (0.53) RAB9ASMN1; SMN2HTTLMNAALDH1A1
SCHEMBL3580133 0.79 LMNA (0.54) POLBRAB9ASMN1; SMN2NR4A3HTT
SCHEMBL15565711 0.79 NPC1 (0.46) POLBRAB9ASMN1; SMN2NR4A3HTT
SCHEMBL1406641 0.78 HCAR3 (0.41) SMN1; SMN2NR4A3ALKBH1ALDH1A1MAPK1
SCHEMBL2806923 0.78 ALDH1A1 (0.45) RAB9ASMN1; SMN2NR4A3HTTLMNA
SCHEMBL26135833 0.77 ALKBH1 (0.37) POLBSMN1; SMN2NR4A3ALKBH1ALDH1A1
SCHEMBL26133999 0.77 SMN1; SMN2 (0.39) POLBRAB9ASMN1; SMN2NR4A3HTT
SCHEMBL966692 0.76 KDM4E (0.41) POLBRAB9ASMN1; SMN2NR4A3HTT
SCHEMBL1407149 0.76 ALKBH1 (0.37) SMN1; SMN2NR4A3HTTALKBH1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 WO disclosed
EP-1320527-B1 METHOD FOR PRODUCING 1 SUBSTITUTED 5-CHLORO-4 METHYL PYRAZOLES BASF SE (DE) 2008-08-13 EP disclosed
US-7002023-B2 Method for producing 1 substituted 5-chloro-4 methly pyrazoles BASF AKTIENGESELLSCHAFT (DE) 2006-02-21 US disclosed
US-20040102505-A1 Method for producing 1 substituted 5-chloro-4 methly pyrazoles BASF AKTIENGESELLSCHAFT (DE) 2004-05-27 US disclosed
US-6515139-B1 A process for preparing N-substituted 2-pyrazolin-5-ones of the formula I h R is C1-C8-alkyl, C5-C8-cycloalkyl, phenyl, naphthyl or phenyl- C1-C4-alkyl which may be unsubstituted or may carry one or more substituents which are inert towards BASF AKTIENGESELLSCHAFT (DE) 2003-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102505-A1 Method for producing 1 substituted 5-chloro-4 methly pyrazoles CYP4F2, CYP2F1, CYP4F3 POLB 2749/4885RAB9A 2335/4885SMN1; SMN2 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.